Imagine finding cancer without needing an invasive camera procedure or messy stool samples. This project creates a set of easy, low-cost tests—like checking breath or blood—to spot early warning signs. It also uses a smart app and AI to tell people their specific risk based on their lifestyle and genes.
Low patient compliance with invasive colorectal cancer screenings and the low sensitivity of current non-invasive tests lead to missed early detections. This results in higher mortality rates and increased healthcare costs.
Four diagnostic tools (ONCO-VOC, ONCO-CRISPR, ONCO-NMR, ONCO-CTC), an AI-powered risk stratification system, a patient self-monitoring mobile app, and a policy-maker analytics dashboard.
If you are a diagnostic kit manufacturer dealing with low patient compliance for invasive tests — this project developed four new diagnostic solutions (ONCO-VOC, ONCO-CRISPR, ONCO-NMR, ONCO-CTC) that provide a less intrusive and more patient-friendly way to detect cancer.
If you are a health app developer dealing with low user engagement in preventative care — this project developed a mobile app for self-monitoring and awareness that helps users track their risk factors.
If you are a health insurer dealing with high costs of late-stage cancer treatment — this project developed a risk-based stratification methodology to identify high-risk individuals early, potentially lowering long-term care costs.
Based on available project data, the project aims to develop 'low-cost' screening technologies, though specific price points per test are not listed.
The project involves 14 industry partners and a clinical validation study with 4100 patients, suggesting a design intended for population-level scaling.
Based on available project data, specific licensing terms are not provided, but the consortium includes 11 SMEs and 14 industry partners to ensure financial viability.
The project runs from 2023-01-01 to 2026-12-31, with clinical validation occurring in phases during this period.
The project includes an Intelligent Analytics dashboard specifically for policy makers to facilitate regional and national health policy making.
The project is highly commercial-ready, featuring a strong industry presence with 14 industrial partners (33% of the consortium) and 11 SMEs. With 43 partners across 16 countries, the group balances technical solution providers, hospitals, and insurance companies, ensuring the resulting tools are validated both clinically and economically.
Contact EXUS SOFTWARE MONOPROSOPI ETAIRIA PERIORISMENIS EVTHINIS in Greece
Contact us to connect with the ONCOSCREEN consortium for licensing opportunities.
